Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Inflammatory Bowel Diseases

Free Subscription Articles published in Drugs Retrieve available abstracts of 15 articles: HTML format

Single Articles

September 2023
1. BLAIR HA
   Ritlecitinib: First Approval.
   Drugs. 2023;83:1315-1321.
   PubMed     Abstract available
   
   
   July 2023
2. GISBERT JP, Chaparro M
   Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
   Drugs. 2023 Jul 28. doi: 10.1007/s40265-023-01916.
   PubMed     Abstract available
   
   
   
3. VUYYURU SK, Shackelton LM, Hanzel J, Ma C, et al
   Targeting IL-23 for IBD: Rationale and Progress to Date.
   Drugs. 2023;83:873-891.
   PubMed     Abstract available
   
   
   
4. KEAM SJ
   Mirikizumab: First Approval.
   Drugs. 2023;83:1045-1052.
   PubMed     Abstract available
   
   
   May 2023
5. SKJELLERUDSVEEN BM, Skoie IM, Dalen I, Grimstad T, et al
   The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
   Drugs. 2023 May 23. doi: 10.1007/s40265-023-01888.
   PubMed     Abstract available
   
   
   March 2023
6. NUNEZ P, Quera R, Yarur AJ
   Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
   Drugs. 2023;83:299-314.
   PubMed     Abstract available
   
   
   November 2022
7. HOY SM
   Deucravacitinib: First Approval.
   Drugs. 2022;82:1671-1679.
   PubMed     Abstract available
   
   
   September 2022
8. PAIK J
   Correction to: Ozanimod: A Review in Ulcerative Colitis.
   Drugs. 2022 Sep 1. pii: 10.1007/s40265-022-01772.
   PubMed    
   
   
   August 2022
9. PAIK J
   Ozanimod: A Review in Ulcerative Colitis.
   Drugs. 2022 Aug 22. pii: 10.1007/s40265-022-01762.
   PubMed     Abstract available
   
   
   July 2022
10. CRISPINO F, Grova M, Bruno EM, Monachino N, et al
    Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets.
    Drugs. 2022 Jul 28. pii: 10.1007/s40265-022-01750.
    PubMed     Abstract available
    
    
    June 2022
11. DHILLON S
    Carotegrast Methyl: First Approval.
    Drugs. 2022;82:1011-1016.
    PubMed     Abstract available
    
    
    August 2021
12. HANZEL J, Ma C, Vande Casteele N, Khanna R, et al
    Correction to: Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Drugs. 2021 Aug 28. pii: 10.1007/s40265-021-01596.
    PubMed    
    
    
    January 2021
13. HANZEL J, Ma C, Casteele NV, Khanna R, et al
    Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.
    Drugs. 2021 Jan 5. pii: 10.1007/s40265-020-01460.
    PubMed     Abstract available
    
    
    March 2020
14. VUITTON L, Peyrin-Biroulet L
    Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease.
    Drugs. 2020;80:385-399.
    PubMed     Abstract available
    
    
    February 2020
15. KIM H, Alten R, Avedano L, Dignass A, et al
    The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
    Drugs. 2020;80:99-113.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.